N. Scher

U.S. Food and Drug Administration drug approval summaries: imatinib mesylate, mesna tablets, and zoledronic acid.

Alison Martin, R. Pazdur, Martin H. Cohen, 2002, The oncologist.

Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastases.

R. Pazdur, J. Gobburu, R. Sridhara, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

First FDA Approval of Dual Anti-HER2 Regimen: Pertuzumab in Combination with Trastuzumab and Docetaxel for HER2-Positive Metastatic Breast Cancer

R. Pazdur, B. Rellahan, P. Cortazar, 2013, Clinical Cancer Research.

acute leukemia End points to establish the efficacy of new agents in the treatment of

R. Arceci, R. Larson, M. Tallman, 2013 .

leukemia Endpoints to establish the efficacy of new agents in the treatment of acute

R. Arceci, R. Larson, M. Tallman, 2013 .

FDA Approval Summary: Pertuzumab for Adjuvant Treatment of HER2-Positive Early Breast Cancer

L. Howie, K. Goldberg, R. Pazdur, 2018, Clinical Cancer Research.

Report from the FDA Approval Summary for Zoledronic Acid for Treatment of Multiple Myeloma and Cancer Bone Metastases

R. Pazdur, J. Gobburu, R. Sridhara, 2003 .

Protein kinases in chronic lymphocytic leukemia.

C. Chung, N. Scher, R. Silber, 1980, Blood.

End points to establish the efficacy of new agents in the treatment of acute leukemia.

J. Radich, R. Arceci, R. Larson, 2007, Blood.

A PET-based nomogram for oropharyngeal cancers.

J Castelli, A Depeursinge, John O. Prior, 2017, European journal of cancer.

Cyclic adenosine 3':5'-monophosphate phosphodiesterase activity in normal and chronic lymphocytic leukemia lymphocytes.

N. Scher, R. Silber, V. G. Malathi, 1976, Cancer research.